Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks

Pain

Volumn 67, Issue 2-3, 1996, Pages 375-378

  May, A ^a   Gijsman, H J ^b   Wallnofer A ^c   Jones, R ^c   Diener, H C ^a   Ferrari, M D ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

endothelin receptor antagonist; migraine; neurogenic inflammation; trigeminovascular system

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIGRAINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASOCONSTRICTION;

EID: 0030273533     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3959(96)03137-5     Document Type: Article

References (14)

1. Brändli, P., Löffler, B.M., Breu, U., Osterwalder, R., Maire J.P. and Clozel, M., Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater, Pain, 64 (1996) 315-322.
2. Buzzi, M.G, and Moskowitz, M.A., The anti-migraine drug sumatriptan (GR 43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater, Br. J. Pharmacol., 99 (1990) 202-206.
3. Clozel, M., Breu, V., Burri, K., et al., Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist, Nature, 25 (1993) 179-84.
4. Clozel, M., Breu, V. and Gray, G.A., Pharmacological characterisation of bosentan, a new potent orally active non-peptide endothelin receptor antagonist, J. Pharmacol. Exp. Then., 270 (1994) 228-235.
5. Färkkilä, M., Jorma, P., Saijonmaa, O. and Fyhrquist, F., Raised plasma endothelin during acute migraine attack, Cephalalgia, 12 (1992) 383-384.
6. Ferrari, M.D. and Saxena, P.R., Clinical and experimental effects of sumatriptan in humans, Trends Pharmacol, Sci., 14 (1993) 129-134.
7. Ferrari, M.D. for The Subcutaneous Sumatriptan International Study Group, Treatment of migraine attacks with sumatriptan, N. Engl. J. Med., 325 (1991) 316-321.
8. Hamblen, T.J., Endothelins, Br. Med. J., 301 (1990) 5688.
9. Headache Classification Committee of the International Headache Society, Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia, 8 (Suppl. 7) (1988) 1-9.
10. Humphrey, P.P.A, and Feniuk, W., Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci., 12 (1991) 444-446.
11. Moskowitz, M.A., The neurobiology of vascular head pain, Ann. Neurol., 16 (1984) 157-168.
12. Moskowitz, M.A., Neurogenic vs. vascular mechanisms of sumatriptan and ergot alkaloids in migraine, Trends Pharmacol. Sci., 13 (1992) 307-311.
13. Saito, K., Markowitz, S. and Moskowitz, M.A., Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches, Ann. Neurol., 24 (1988) 732-737.
14. Yanagisawa, M., Inoue, A., Ishikawa, T., et al., Primary structure, synthesis and biological rat endothelin and endothelin derived vasocon-stricture peptide, Proc. Natl. Acad. Sci. USA, 85 (1988) 6964-6967.